Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant
The elinzanetant molecule does not show any of the known structural features that have been associated with hepatotoxicity [9-12] and does not share similar substructures with other NK-3 receptor antagonists (Fig. 1).
Authors
- Mila Trajanovic
- Yves Horsmans (ORCID: https://orcid.org/0000-0002-5779-2454)
- R Stuart Anderson
- Lineke Zuurman
- Dominique Larrey (ORCID: https://orcid.org/0000-0002-0892-3489)
- Esther Groettrup‐Wolfers (ORCID: https://orcid.org/0000-0003-1840-8015)
- James H. Lewis (ORCID: https://orcid.org/0000-0002-6686-3744)
- Raúl J Andrade
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- Bayer (United States) (US)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- Centre Hospitalier Universitaire de Montpellier (FR)
- MRC Centre for Reproductive Health (GB)
- Bayer (Switzerland) (CH)
- Hôpital Saint Eloi (FR)
- Instituto de Investigación Biomédica de Málaga (ES)
- Bayer (Germany) (DE)
- University of Edinburgh (GB)
Publication Details
- Journal
- Drug Safety
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1007/s40264-026-01675-5
- Primary Topic
- Neuropeptides and Animal Physiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00